At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 112 enrolled
Drug / intervention
Mavacamten +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
In Brief
A Phase 3 clinical trial evaluating Mavacamten and Placebo for HOCM, Hypertrophic Obstructive Cardiomyopathy. Completed, enrolled 112 participants across 21 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multi-center study in the United States (U.S.) that will evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM \[also known as HOCM\]) who are eligible for SRT based on ACCF/AHA 2011 and/or ESC 2014 guidelines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJul 2020
Primary CompletionFeb 2022
Study CompletionMay 2024
TodayJul 2026
First PostedApr 16, 2020
Enrollment StartJul 6, 2020
Primary CompletionFeb 7, 2022
Study CompletionMay 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.2 years ago
Interventions
Mavacamtendrug
Mavacamten Capsules Other names: MYK-461
Placebodrug
Placebo